Sox2 is an important transcriptional regulator in embryonic and adult stem cells [1] [2] [3] [4] . Recently, Sox2 was identified as an oncogene in many endodermal cancers, including colon cancer [5] [6] [7] [8] . There is great interest in how Sox2 cooperates with other transcription factors to regulate stem cell renewal, differentiation, and reprogramming [9] . However, we still lack a general understanding of Sox2 transcriptional action. To determine transcriptional partners of Sox2 in adult cells, we generated mice where gene expression could be induced by an externally applied stimulus. We analyzed the consequences in the intestine where cell turnover is rapid. Sox2 expression, but not Oct4, specifically increased the numbers of stem cells and repressed Cdx2, a master regulator of endodermal identity. In vivo studies demonstrated that Sox21, another member of the SoxB gene family, was a specific, immediate, and cell-autonomous target of Sox2 in intestinal stem cells. In vitro experiments showed that Sox21 was sufficient to repress Cdx2 in colon cancer cells and in pluripotent stem cells. Sox21 was also specifically induced by Sox2 in fibroblasts and inhibition of Sox21 blocked reprogramming to the pluripotent state. These results show that transcriptional induction of Sox21 is a rapid and general mediator of the effects of Sox2 on cell identity in a wide range of cell types.
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Results and Discussion
Inducing Sox2 in the Adult Intestine To study the function of Sox2 in adult tissues, we employed an inducible overexpression strategy [10] . We focused on the intestine because the short life-cycle of differentiated cells allows rapid analysis of tissue homeostasis [11] .
Morphological changes were observed in the intestine following 2-day Sox2 induction ( Figure 1A ; see Figure S1A available online). When the bromodeoxyuridine (BrdU) analog ethynyl-2 0 -deoxyuridine (EdU) was administered for 3 hr on day 2 of DOX treatment, an increase in the number of proliferating cells was observed ( Figures 1A, 1C 0 , and 1D). The majority of EdU labeled cells were Sox2-positive ( Figure 1D ) and crypts became morphologically expanded ( Figures  1C-1C 00 ; Figure S1A ). When a pulse of EdU labeling was followed by a 3-day chase, EdU-positive cells were found throughout the villi ( (Figures S1F-S1I ). These data suggest that Sox2 stimulates the proliferation of precursor cells that subsequently differentiate into the major cell types of the intestine.
There are two populations of proliferating cells in the intestine, transit amplifying progenitors (TAP), and intestinal stem cells (ISCs) [12] . Prominin1 (Prom1) marks both populations whereas Lgr5 is expressed in ISCs [13, 14] . Upon Sox2 induction, Prom1 expression was markedly extended toward the crypt-villus boundary ( Figures 1G and G 0 ). Lgr5-GFP positive cells were also dramatically expanded ( Figures 1A, 1H , and 1H 0 ). Neither Lgr5 + nor Prom1 + cells were detected in the villi. The coexpression of EdU and Sox2 in the nuclei of Lgr5-GFP + cells suggests that Sox2 directly affects the number and location of ISCs ( Figure 1D ).
Paneth cells provide niche signals for ISCs [15] . Sox2-activated, proliferating Lgr5-positive cells were seen that had no direct contact with Lysozyme + Paneth cells but these ectopic cells were restricted to the crypt ( Figure 1E ). These results show that the induction of Sox2 is associated with a disruption in the signaling that normally restricts Lgr5 to the base of the crypt but differentiation in the villi is accompanied by downregulation of Lgr5.
Wnt signaling is important for maintaining stem and progenitor cells in the intestine [12, [16] [17] [18] and Lgr5 was recently identified as a coreceptor for Frizzled/Lrp Wnt receptor [19] . Wnt targets, including Lgr5, Myc, CD44, Ephb2, and cyclinD1, were upregulated on day 2 of Sox2 induction ( Figure S1B ). CD44, which is normally restricted to the crypt [17] , was present throughout the crypt-villus unit after induction of Sox2 ( Figure S1C ). Olfm4, another marker of intestinal stem cells [20] , was also dramatically upregulated (data not shown).
EphB2 and EphB3 receptors are expressed in the crypts, whereas the ephrin ligands are expressed in the villi [21, 22] . Upon Sox2 induction, EphB2 was upregulated in the villus and Ephrin B1 staining extended into the crypt (Figures S1D and S1E). Thus, Sox2 induction disrupts some features of the crypt-villus organization but maintains the crypt as the main site of cell proliferation.
Distinct Effects of Sox2 and Oct4 on Intestinal Precursor Cells
Previous studies with TetON-Oct4 mice showed increased proliferation in the intestine but did not specifically define the proliferating cells [10] . Consistent with published data, a clear proliferative response was seen after 2 days of DOX treatment in TetON-Oct4 mice ( Figures S2A-S2C ). The presence of many EdU labeled cells in the neck of the crypt after Oct4 induction and the elevated expression of Prominin1 (data not shown) suggest expansion of TAPs. Surprisingly, Lgr5 expression was not elevated and the Lgr5 cells remained restricted to the base of the crypt after Oct4 induction ( Figure 1A ; Figures S2D-S2F ).
Transcriptional Consequences of Sox2 and Oct4
Expression Microarray data on gene expression patterns was used to define the specific transcriptional effects of Sox2 compared *Correspondence: ronald.mckay@libd.org to Oct4. Cluster analysis of the entire data set shows that the transcriptome of TetON-Oct4 animals was clearly different from that of the Sox2-induced animals ( Figure S2H ). Interestingly, when TetON-Sox2 and TetON-Oct4 mice were crossed, the transcriptome (+DOX) of the double-induced animals showed marked similarity to the transcriptome of TetONSox2 mice ( Figures S2G and S2H ). These results show that induction of Sox2 but not Oct4 increased Lgr5 expression.
Many intestinal genes, including Vil1, Fabp2, intestinal alkaline phosphatase (ALPI), peptide Y (Pyy), Muc13, Muc3, Mucdhl, and Tff3, were downregulated by Sox2 and many anterior genes were upregulated, including keratins (Krt1-15, Krt1-13, Krt2-4, Krt2-6a, Krt1-23, Krt2-5), Pkp1, and dermokine (1110014F24Rik) (Figures 2A and 2C ; Figure S2K ). Alongside Sox2, Foxa2 is required for the differentiation of the anterior endoderm and is expressed in esophagus, trachea, lung, pancreas, and liver [23] [24] [25] . On Sox2 induction, Foxa2 became upregulated in the adult intestine (Figures 2A and  2C ; Figure S2L ).
During development, Sox2 is expressed in the anterior endoderm and this expression is antagonized by the master regulator of posterior endoderm Cdx2 [26] . Cdx2 expression was clearly reduced in the intestines of 2-day Sox2-induced animals ( Figure 2B ). Transcription factors regulated by Cdx2 including Klf4, HNF1a, Hnf4a, and Isx were downregulated and anterior transcriptional regulators including Pax9 and Pitx1 were induced ( Figure 2C ; Figure S2K ). Oct4 did not repress Cdx2 (Figure S2J ), the Cdx2 targets Klf4, Hnf1a, Hnf4a, and Isx, or intestinal markers Vil1, Fabp2, and ALP, nor did it upregulate anterior markers and keratins (data not shown). These results suggest that Sox2 induction reprograms the positional identity of cells in vivo.
Sox21 Induction Is a Specific and Cell-Autonomous Target of Sox2
Because Sox2 is thought to be a transcriptional activator, we searched for Sox2 activated repressors by comparing lists of DOX-induced genes. In TetON-Sox2 intestines, mouse embryonic fibroblasts (MEFs), embryonic stem cells (ESCs), and neural stem cells, we found that Sox21, a SoxB family transcriptional repressor, was strongly upregulated by Sox2 (data not shown). Sox21 induction was confirmed in the intestine as early as 16 hr after Dox treatment ( Figures 2C and 2D) , concomitant with repression of Cdx2 and preceding the increase in cell proliferation, expansion of Lgr5 + cells, or the induction of Krt13 (data not shown). Oct4 did not induce Sox21 ( Figure S2I ).
For Sox21 to act as an endogenous mediator of Sox2 initiated transcriptional change, the two proteins must be expressed in the same cells. To study whether Sox21 is a cell-autonomous target of Sox2, we specifically induced Sox2 in Lgr5
+ cells using a combination of cre-dependent tTA and Lgr5-EGFP-IRES-creER alleles (see Supplemental Experimental Procedures). A low dose of tamoxifen was used to induce 
Sox2 in single Lgr5-EGFP-expressing cells. Four days after Tam injection, Sox2 expressing cells were seen in 10% of crypts. In all Sox2
+ crypts trains of Lgr5 + ,Sox2 + cells were seen extending into the neck of the crypt ( Figure S2M ). Aberrantly localized Lgr5 + cells were never seen in normal, uninduced crypt-villus units ( Figure S2N ). One hundred percent of mislocalized Lgr5 + ,Sox2 + cells upregulated Sox21 ( Figure 2E ; Figure S2O ), suggesting that Sox2 cell-autonomously induces Sox21.
To test whether Sox21 can repress Cdx2, we used the human colon cancer cell line Ls174T that expresses Cdx2 but neither Sox2 nor Sox21 [27] . Cdx2 expression was diminished in cells stably transfected with Sox21 ( Figure 3A) . In these cells, chromatin immunoprecipitation (ChIP) demonstrated that Sox21 was present on the Cdx2 enhancer [28] (Figure 3B) . We compared the ability of Sox2, Sox21, and Oct4 to repress Cdx2 directly. As seen from Figure 3C , Sox21, but not Sox2 or Oct4, strongly reduced the number of Cdx2 + cells. These data show that Sox21 induction is sufficient to repress Cdx2.
Sox21 Regulates the Expression of Cdx2 in Pluripotent Cells
Sox2 and Cdx2 also play important roles in the process of early embryonic lineage segregation [3, 29] and Cdx2 has been shown to repress Sox2 [26] . Our data show that Sox2 can repress Cdx2 and suggest that this effect requires induction of Sox21. To ask whether Sox21 is required for Sox2 to repress Cdx2 in pluripotent cells, we analyzed mouse ESCs containing the TetON-Sox2 transgene. Sox21 protein was upregulated when Sox2 levels increased ( Figure 3D; Figures 3A, and  S3B ), suggesting that Sox2 induces Sox21 in pluripotent cells.
BMP4 causes mouse ESCs to differentiate into Cdx2 + cells [30, 31] . When mouse TetON-Sox2 ESCs were treated with BMP4 for 4 days, Cdx2 expression was upregulated, but maintaining Sox2 expression by treatment with DOX blocked Cdx2 induction ( Figure 3E, left panel) . Transfection of Sox21 siRNA rescued Cdx2 expression ( Figure 3E , right panel; Ant.
Post. Figures 3E, and S3F). Sox21 knockdown was efficient and did not affect levels of Sox2 ( Figures S3C and S3D) . These results show that Sox21 is required for Sox2 to repress Cdx2 expression.
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To confirm Cdx2 repression by Sox21 in physiological conditions, we performed Sox21 ChIP in human ESC-derived neurectodermal progenitors ( Figure 3F ). Sox21 was enriched at the Cdx2 enhancer in neuroectodermal cells obtained by Noggin-SB431542 treatment, but not in BMP4-treated cells. Recently, Sox2 was found to bind the Sox21 enhancer in ES cells undergoing neural differentiation [32] . We confirmed this result (Figure 3G) , further strengthening our argument that Sox2 directly induces Sox21.
Sox21 Induction by Sox2 Is Required to Reprogram Cells
Sox2 is a critical factor that is required for cellular reprogramming so we asked whether Sox21 induction is required for induced pluripotent stem cell (iPSC) generation from fibroblasts. Doxycycline treatment of TetON-Sox2 MEFs rapidly upregulated Sox21 ( Figure 4A ). Similar to intestine, Oct4 did not induce Sox21 ( Figure 4B ). Sox21 induction by Sox2 was unaffected by coexpression of Oct4, or the combination of Oct4, Klf4, and c-Myc ( Figure 4C ). During the reprogramming process we transfected Tet-OSMK MEFs [33] with Sox21 siRNA or control siRNA. Sox21 knockdown resulted in significantly reduced numbers of SSEA1 + colonies compared to the control siRNA ( Figure 4D ). SSEA1 + colonies established in the presence of Sox21 and control siRNA became phenotypically normal iPSCs (Figures S4A-S4D) . Therefore, induction of Sox21 by Sox2 is required to induce the pluripotent stem cell state.
Sox21 is widely expressed in the developing nervous system where it is often coexpressed with Sox2 and these two genes are thought to have opposing roles in neurogenesis [34] [35] [36] [37] [38] [39] . Our data suggest that the interaction of Sox2 and Sox21 should be assessed in the many studies analyzing the mechanisms of reprogramming and neuronal transdifferentiation [40] [41] [42] .
In addition to endoderm, Sox2 and Sox21 intersect with Cdx2 in other systems, such as trophectoderm [43] and caudal neuroectoderm [44] . Our preliminary results show that expression of Sox21 and Cdx2 is mutually exclusive in human ESC-derived hindbrain cultures. There is also increasing evidence that Sox2 acts as an oncogene [5, 6, 8] . The data presented here suggest that it will be important to determine whether the oncogenic function of Sox2 requires genetic or epigenetic silencing of the tumor suppressor Sox21. Figure S4 .
